More evolution of the evidence in asthma disease management--SMART versus GOAL clinical trials debate the cost-benefit of LABA while the value of leukotriene modifiers, particularly montelukast, is uncertain.
Curtiss
Frederic R
FR
D000085:Acetates / Q000191:economics / Q000627:therapeutic use*; D000318:Adrenergic beta-Agonists / Q000191:economics / Q000627:therapeutic use*; D001249:Asthma / Q000188:drug therapy* / Q000191:economics; D002986:Clinical Trials as Topic; D003362:Cost-Benefit Analysis; D003521:Cyclopropanes; D003692:Delayed-Action Preparations; D019468:Disease Management; D004632:Emergency Medical Services; D005938:Glucocorticoids / Q000191:economics / Q000627:therapeutic use; D006760:Hospitalization; D006801:Humans; D007345:Insurance Claim Review; D020024:Leukotriene Antagonists / Q000191:economics / Q000627:therapeutic use*; D011804:Quinolines / Q000191:economics / Q000627:therapeutic use*; D013440:Sulfides
D000085:Acetates; D000318:Adrenergic beta-Agonists; D003521:Cyclopropanes; D003692:Delayed-Action Preparations; D005938:Glucocorticoids; D020024:Leukotriene Antagonists; D011804:Quinolines; D013440:Sulfides; C093875:montelukast